Under the agreement, Delrus will distribute MagForce’s NanoTherm therapy in the Russian Federation, Belarus Republic, Republic of Kyrgyzstan, Republic of Kazakhstan, Ukraine, Republic of Tajikistan and Republic of Uzbekistan.

Delrus will also be responsible for obtaining marketing authorization of NanoTherm therapy for the treatment of brain tumors in these countries.

MagForce said upon an equivalent approval of the NanoTherm therapy, the agreement will be extended to other tumor indications.

Delrus president July Magadeev said, "We look forward to the opportunity to introduce nanomedicine in oncology to the medical market in Russia and further CIS countries and professionally support its usage among oncology specialists and in hospitals."

MagForce is planning to participate in Russian medical centers for conducting international clinical studies as well as to expand the scope of technology application for the treatment of other forms of cancer.